| 摘要 |
The present disclosure provides methods for gene therapy utilizing hematopoietic stem cells, lymphoid progenitor cells, and/or myeloid progenit or cells. The cells are genetically modified to provide a gene that is expresse d in these cells and their progeny after differentiation. In a preferred embodiment the cells contain a gene or gene fragment that confers to the cel ls resistance to HIV infection and/or replication. The cells are administered t o a patient in conjunction with treatment to reactivate the patient's thymus. The cells may be autologous, syngeneic, allogeneic or xenogeneic, as toleran ce to foreign cells is created in the patient during reactivation of the thymus . In a preferred embodiment the hematopoietic stem cells are CD34+. The patient's thymus is reactivated by disruption of sex steroid mediated signaling to the thymus. In a preferred embodiment, this disruption is creat ed by administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines or combinations thereof. |
